Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/616,502external-prioritypatent/US4959457A/en
Priority claimed from DK241385Aexternal-prioritypatent/DK171531B1/da
Application filed by Genentech IncfiledCriticalGenentech Inc
Publication of DK56995ApublicationCriticalpatent/DK56995A/da
Application grantedgrantedCritical
Publication of DK172382B1publicationCriticalpatent/DK172382B1/da
Isoleret biologisk aktivt humant lymphotoxinderiv at og antistof som neutraliserer den cytolytiske aktivitet af dette, nucleinsyre som koder for lymphotoxinderivatet, replikerbar vektor omfattende nucleinsyren, heterolog celle transformeret med nucleinsyren og fremgangsmåde som omfatter fremstilling af lymphotoxinderivatet.
"composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion".
Pancreatic secretory trypsin inhibitor variants, their production, expression vectors and recombinant hosts therefor and pharmaceutical compositions containing them